Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Purespring Therapeutics has secured approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002.

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoingCash and cash equivalents of $83.5 million as of June 30, ...

GAAP EPS loss widened to $(1.22) from $(1.10) year over year in Q2 2025 as R&D expenses rose 47.7% and G&A expenses climbed 48.8% compared to Q2 2024. VAX-31 vaccine program advanced with FDA expanded ...

Key Points GAAP revenue surged to $4.0 million in Q2 2025, beating analyst expectations by 381.9%. GAAP net loss per share improved to $(0.50) in Q2 2025, slightly better than the estimated $(0.52).

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

The US Department of Health and Human Services has terminated 22 mRNA vaccine research contracts under BARDA, signaling a ...

The Trump administration on Tuesday eliminated 22 mRNA vaccine development projects for COVID-19 and bird flu, a stark shift away from technology credited with bringing the United States out of the ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Chronic rare diseases are becoming a major challenge for the aging population in the United States. As life expectancy rises, ...

Gain insights into Lexicon Pharmaceuticals' Q2 2025 earnings call including R&D progress, cost savings, partnership updates, and a shift to net profitability.